openPR Logo
Press release

ICRC-Weyer, Allied Clinical Management Form MEDIS Research Group

11-14-2013 07:14 PM CET | Health & Medicine

Press release from: ICRC-Weyer GmbH

MEDIS Research Group Logo

MEDIS Research Group Logo

In a move to better meet requirements of clinical trial sponsors, ICRC-Weyer and Allied Clinical Management have entered into a strategic partnership by forming MEDIS Research Group. The partnership will enable the two CROs to combine clinical research expertise and to provide complete service solutions across all stages of the clinical development process.

The decision to form MEDIS Research Group came as a reaction to a shift in the market towards consolidation in the industry that could be observed over the last few years. ICRC-Weyer and Allied Clinical Management, both based in Berlin, have been successfully working together on several clinical trial projects, with Allied Clinical Management handling trial conduct, site management and monitoring, while ICRC-Weyer delivers “back-office” services such as clinical data management, biostatistics and medical writing.

‘The cooperation between our two companies has been very good and successful’ says Simone Ahrens, Managing Director of ICRC-Weyer. ‘We think it is the right time now to fully combine our expertise and deliver our services under the name of this newly formed joint venture. This will enable us to help pharmaceutical and biotech companies as well as medical device manufacturers and nutraceuticals managing their entire trial projects for them – the complete range of services from one hand.’

Momentarily, MEDIS Research Group consists of ICRC-Weyer and Allied Clinical Management. However, the two companies are already in discussions with clinical research services providers, such as clinical laboratories and medical communication experts that they have already working with in the past, to join the group and to complete the complete range of clinical trial services from protocol design to writing the final clinical study report.

Michael Roehl, Managing Director of Allied Clinical Management, adds: ‘Consolidation and Specialization. These are two of the major business challenges our industry has been facing over the last few years. With our trial conduct experience in areas such as oncology and cardiovascular diseases and ICRC-Weyer’s highly specialized medical data management and data analysis services, trial sponsors can draw from our clinical research expertise to receive best value for money for their clinical trial projects.’

In order to provide a single service point for their clients, the two companies have developed and implemented SOPs to streamline their collaboration processes. This ensures that there is one main contract with the client and one contact person who will guide the client’s clinical trial project from commencement to its successful conclusion.

About ICRC-Weyer:
ICRC-Weyer is an established all-phase contract research organization (CRO) based in Berlin, Germany. The company was founded in 1993 by Prof. Dr. Geerd Weyer and provides clinical research services for Medicinal Products, Medical Devices, Advanced Therapies and Nutraceuticals. Services include Data Management, Biostatistics, Monitoring and Medical Review for all stages of the clinical development process.
ICRC-Weyer’s core expertise is built around Automated CDISC Mapping, Medical Coding, Safety Writing and Added Value Dossiers (AMNOG).

About Allied Clinical Management:
Allied Clinical Management specializes in planning, managing and on-site monitoring of phase I to phase IV post-marketing clinical trials. ACM was founded in 2004 by Michael Roehl and has offices in downtown Berlin and near the internationally renowned Biotech Park in the northern district of Berlin-Buch. Allied Clinical Management is an audited member of German Federation of Contract Research Organizations (BVMA e.V. ) since 2009.

ICRC-Weyer GmbH
Martin Krainz
Boelschestrasse 2
12587 Berlin
Germany
Phone: +49 30 403937-116

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release ICRC-Weyer, Allied Clinical Management Form MEDIS Research Group here

News-ID: 275469 • Views:

More Releases from ICRC-Weyer GmbH

ICRC-Weyer To Expand Pharmacovigilance Services For Mid-Sized Pharma Companies
ICRC-Weyer To Expand Pharmacovigilance Services For Mid-Sized Pharma Companies
In a move to better meet drug-safety related service requirements by small to mid-sized pharmaceutical sponsors ICRC-Weyer has expanded its services portfolio in regards to pharmacovigilance and pharmacovigilance writing. ‘Our pharmacovigilance services comprise SAE/AE reporting as well as writing Development Safety Update Reports, Periodic Safety Update Reports, Risk Management Plans and more’ says Dr Ulrike Treichel, Head of Pharmacovigilance at ICRC-Weyer. ‘Furthermore, we setup and maintain a validated safety database. We
Clinical CRO ICRC-Weyer To Boost Drug Safety Services For Investigator Trials
Clinical CRO ICRC-Weyer To Boost Drug Safety Services For Investigator Trials
The Berlin-based clinical contract research organization (CRO), ICRC-Weyer GmbH, has announced it will boost its drug-safety related Pharmacovigilance Services for Investigator-Initiated Trials amid an increasing demand by trial sponsors. An increase in the number of requests by trial sponsors for regulatory-compliant drug safety reporting for investigator-initiated trials (IITs) has led the German CRO ICRC-Weyer to amend their services portfolio towards providing these services to large and mid-sized pharmaceutical trial sponsors. ‘A large
ICRC-Weyer To Enhance Pharmacovigilance Risk Management
ICRC-Weyer To Enhance Pharmacovigilance Risk Management
The Berlin-based clinical contract research organization (CRO) ICRC-Weyer has made further enhancements to their Pharmacovigilance risk management. By integrating medical review procedures into the Pharmacovigilance system the company is now able to provide efficient risk management strategies in line with current market and regulatory developments. The decision to pursue this integration process was made following ICRC-Weyer’s recent participation at the Evolution Summit in Munich, Germany, an industry forum bringing together representatives
ICRC-Weyer Clinical CRO Looks Back At A Successful Year 2012
ICRC-Weyer Clinical CRO Looks Back At A Successful Year 2012
The management of ICRC-Weyer GmbH looks back at a successful year 2012, with a number of new collaborations and partnerships in the area of outsourcing clinical services. According to J. Daniel Weyer, Managing Director at ICRC-Weyer, the success results from the hard work of a devoted team combined with the company’s constant enhancements to their existing services portfolio. ‘A lot has happened this year’ says Mr Weyer. ‘We have successfully adjusted

All 5 Releases


More Releases for Weyer

Global Neonatal Incubator Market - AHT, Natus Medical, Weyer GmbH, Fanem
The report that is written on the title Neonatal Incubator Market covers all across the globe, recently added to the repository of Market Research, is titled ‘Global Neonatal Incubator Market 2017’. The research report analyses the historical as well as present performance of the worldwide Neonatal Incubator industry, and makes predictions on the future status of Neonatal Incubator market on the basis of this analysis. An infant incubator is a
ICRC-Weyer To Expand Pharmacovigilance Services For Mid-Sized Pharma Companies
In a move to better meet drug-safety related service requirements by small to mid-sized pharmaceutical sponsors ICRC-Weyer has expanded its services portfolio in regards to pharmacovigilance and pharmacovigilance writing. ‘Our pharmacovigilance services comprise SAE/AE reporting as well as writing Development Safety Update Reports, Periodic Safety Update Reports, Risk Management Plans and more’ says Dr Ulrike Treichel, Head of Pharmacovigilance at ICRC-Weyer. ‘Furthermore, we setup and maintain a validated safety database. We
ICRC-Weyer To Enhance Pharmacovigilance Risk Management
The Berlin-based clinical contract research organization (CRO) ICRC-Weyer has made further enhancements to their Pharmacovigilance risk management. By integrating medical review procedures into the Pharmacovigilance system the company is now able to provide efficient risk management strategies in line with current market and regulatory developments. The decision to pursue this integration process was made following ICRC-Weyer’s recent participation at the Evolution Summit in Munich, Germany, an industry forum bringing together representatives
ICRC-Weyer Clinical CRO Looks Back At A Successful Year 2012
The management of ICRC-Weyer GmbH looks back at a successful year 2012, with a number of new collaborations and partnerships in the area of outsourcing clinical services. According to J. Daniel Weyer, Managing Director at ICRC-Weyer, the success results from the hard work of a devoted team combined with the company’s constant enhancements to their existing services portfolio. ‘A lot has happened this year’ says Mr Weyer. ‘We have successfully adjusted
Clinical CRO ICRC-Weyer Ready For Increase In Advanced Therapy Trials
ICRC-Weyer’s recent participation in the NanoKTN biotechnology meeting in Berlin proved to be both informative and successful. The event which took place at the British Embassy in Berlin on September 5th, 2012 was attended by two members of the ICRC-Weyer team. The meeting provided a platform for biotech companies and service providers from the UK and Germany to present their work in the field of regenerative medicine and engage in
New Medical Coding Procedures At Clinical CRO ICRC-Weyer
ICRC-Weyer GmbH has announced an enhancement to their medical coding procedures for drug development processes. Until recently, the company had been utilizing limited licenses for the coding dictionary of the World Health Organization WHO (WHO DD/WHO Drug). WHO DD is an international classification of medicines created by the WHO Programme for International Drug Monitoring and managed by the Uppsala Monitoring Centre. It is used by pharmaceutical companies, clinical trial organizations